Study of the mapping of pharmaceutical manufacturers in Korea for the Health Emergency Preparedness and Response Authority (HERA)

This analytical study provides a comprehensive overview of the pharmaceutical manufacturing landscape in South Korea, covering generics, vaccines, diagnostics, APIs, and PPE. The data is drawn from a total of 653 registered Korean pharmaceutical companies, with a focus on major players distinguished by their revenue. Detailed company profiles and product listings are available in Annexes. South Korea's pharmaceutical market, which grew by 16.7% in 2022 to USD 22.4 billion, is a robust and expanding sector. This growth reflects an increase in both imports and exports, with domestic production standing at USD 21.7 billion, 37.3% of which is exported. Korea is a notable player in the global pharmaceutical industry, ranking as the world's fifth-largest clinical trial market and a leader in biosimilars. Since 2019, the country has been included on the EU Whitelist, underscoring its growing international influence. The Korean pharmaceutical sector is characterized by world-class biopharmaceutical production facilities, driven by government-led initiatives, and a burgeoning presence in overseas investments.